{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43","upperLimit":"87","value":"71"}]}],"title":"Percent Overall Survival at 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31","upperLimit":"78","value":"58"}]}],"title":"Percent Overall Survival at 2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of survival","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.\n\nlenalidomide: Given PO","id":"OG000","title":"Treatment (Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"Patients enrolled on trial who received lenalidomide therapy.","reportingStatus":"POSTED","timeFrame":"At 1 and 2 years after starting treatment with lenalidomide","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}